Xilio Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Xilio Therapeutics, Inc. carries a market capitalization of 59.18M, placing it among publicly traded companies globally. Its enterprise value stands at -66.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 59.18M |
| Enterprise Value | -66.70M |
Share Statistics
Xilio Therapeutics, Inc. currently has 6.58M shares outstanding.
| Shares Outstanding | 6.58M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.73, and the price-to-book ratio stands at 0.87.
| PE Ratio | N/A |
| PS Ratio | 1.73 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | -1.93 |
| P/OCF Ratio | -1.83 |
Enterprise Valuation
| EV / Sales | 0.78 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Xilio Therapeutics, Inc. maintains a current ratio of 4.25, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.25 |
| Quick Ratio | 4.15 |
| Debt / Equity | 8.72 |
| Debt / EBITDA | -0.21 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -55.03 |
| Return on Assets (ROA) | -15.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Xilio Therapeutics, Inc.'s stock has declined approximately -16.04478% over the past 52 weeks. The 50-day moving average sits at 9.03, while the 200-day moving average is 8.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -16.04478% |
| 50-Day Moving Average | 9.03 |
| 200-Day Moving Average | 8.61 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Xilio Therapeutics, Inc. generated 64.09M in revenue and converted that into -21.83M in net income, yielding earnings per share of -1.81. EBITDA reached -30.03M, while operating income came in at -31.37M.
| Revenue | 64.09M |
| Gross Profit | N/A |
| Operating Income | -31.37M |
| Pretax Income | -21.83M |
| Net Income | -21.83M |
| EBITDA | -30.03M |
| EBIT | -31.37M |
| Earnings Per Share (EPS) | -1.81 |
Balance Sheet
Xilio Therapeutics, Inc. holds 136.04M in cash and equivalents against 6.30M in total debt, resulting in a net debt position of -136.04M. Total book value stands at 72.26M, with working capital of 111.27M providing operational flexibility.
| Cash & Cash Equivalents | 136.04M |
| Total Debt | 6.30M |
| Net Debt | -136.04M |
| Equity (Book Value) | 72.26M |
| Book Value Per Share | 10.98 |
| Working Capital | 111.27M |
Cash Flow
Xilio Therapeutics, Inc. produced -60.60M in operating cash flow over the past twelve months. After subtracting -670,000.00 in capital expenditures, free cash flow totaled -61.27M - equivalent to -5.29 per share.
| Operating Cash Flow | -60.60M |
| Capital Expenditures | -670,000.00 |
| Free Cash Flow | -61.27M |
| FCF Per Share | -5.29 |
Margins
Xilio Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -48.94 and net profit margin of -34.06 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -48.94 |
| Pretax Margin | -34.06 |
| Profit Margin | -34.06 |
| EBITDA Margin | -46.85 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -120.22 |
| FCF Yield | -51.80 |
Stock Splits
Xilio Therapeutics, Inc.'s most recent stock split took place on March 16, 2026 with a 14:1 split ratio.
| Last Split Date | 3/16/2026 |
| Split Ratio | 14:1 |
Scores
Xilio Therapeutics, Inc. posts an Altman Z-Score of -2.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.87 |